Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A variant at 9q34.11 is associated with HLA-DQB1*06:02 negative essential hypersomnia.
Miyagawa T, Khor SS, Toyoda H, Kanbayashi T, Imanishi A, Sagawa Y, Kotorii N, Kotorii T, Ariyoshi Y, Hashizume Y, Ogi K, Hiejima H, Kamei Y, Hida A, Miyamoto M, Ikegami A, Wada Y, Takami M, Higashiyama Y, Miyake R, Kondo H, Fujimura Y, Tamura Y, Taniyama Y, Omata N, Tanaka Y, Moriya S, Furuya H, Kato M, Kawamura Y, Otowa T, Miyashita A, Kojima H, Saji H, Shimada M, Yamasaki M, Kobayashi T, Misawa R, Shigematsu Y, Kuwano R, Sasaki T, Ishigooka J, Wada Y, Tsuruta K, Chiba S, Tanaka F, Yamada N, Okawa M, Kuroda K, Kume K, Hirata K, Uchimura N, Shimizu T, Inoue Y, Honda Y, Mishima K, Honda M, Tokunaga K. Miyagawa T, et al. Among authors: ishigooka j. J Hum Genet. 2018 Dec;63(12):1259-1267. doi: 10.1038/s10038-018-0518-8. Epub 2018 Sep 28. J Hum Genet. 2018. PMID: 30266950 Clinical Trial.
A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia.
Miyagawa T, Tanaka S, Shimada M, Sakai N, Tanida K, Kotorii N, Kotorii T, Ariyoshi Y, Hashizume Y, Ogi K, Hiejima H, Kanbayashi T, Imanishi A, Ikegami A, Kamei Y, Hida A, Wada Y, Miyamoto M, Takami M, Kondo H, Tamura Y, Taniyama Y, Omata N, Mizuno T, Moriya S, Furuya H, Kato M, Kato K, Ishigooka J, Tsuruta K, Chiba S, Yamada N, Okawa M, Hirata K, Kuroda K, Kume K, Uchimura N, Kitada M, Kodama T, Inoue Y, Nishino S, Mishima K, Tokunaga K, Honda M. Miyagawa T, et al. Among authors: ishigooka j. NPJ Genom Med. 2022 Apr 12;7(1):29. doi: 10.1038/s41525-022-00298-w. NPJ Genom Med. 2022. PMID: 35414074 Free PMC article.
New susceptibility variants to narcolepsy identified in HLA class II region.
Miyagawa T, Toyoda H, Hirataka A, Kanbayashi T, Imanishi A, Sagawa Y, Kotorii N, Kotorii T, Hashizume Y, Ogi K, Hiejima H, Kamei Y, Hida A, Miyamoto M, Imai M, Fujimura Y, Tamura Y, Ikegami A, Wada Y, Moriya S, Furuya H, Kato M, Omata N, Kojima H, Kashiwase K, Saji H, Khor SS, Yamasaki M, Wada Y, Ishigooka J, Kuroda K, Kume K, Chiba S, Yamada N, Okawa M, Hirata K, Uchimura N, Shimizu T, Inoue Y, Honda Y, Mishima K, Honda M, Tokunaga K. Miyagawa T, et al. Among authors: ishigooka j. Hum Mol Genet. 2015 Feb 1;24(3):891-8. doi: 10.1093/hmg/ddu480. Epub 2014 Sep 25. Hum Mol Genet. 2015. PMID: 25256355
A polymorphism in CCR1/CCR3 is associated with narcolepsy.
Toyoda H, Miyagawa T, Koike A, Kanbayashi T, Imanishi A, Sagawa Y, Kotorii N, Kotorii T, Hashizume Y, Ogi K, Hiejima H, Kamei Y, Hida A, Miyamoto M, Imai M, Fujimura Y, Tamura Y, Ikegami A, Wada Y, Moriya S, Furuya H, Takeuchi M, Kirino Y, Meguro A, Remmers EF, Kawamura Y, Otowa T, Miyashita A, Kashiwase K, Khor SS, Yamasaki M, Kuwano R, Sasaki T, Ishigooka J, Kuroda K, Kume K, Chiba S, Yamada N, Okawa M, Hirata K, Mizuki N, Uchimura N, Shimizu T, Inoue Y, Honda Y, Mishima K, Honda M, Tokunaga K. Toyoda H, et al. Among authors: ishigooka j. Brain Behav Immun. 2015 Oct;49:148-55. doi: 10.1016/j.bbi.2015.05.003. Epub 2015 May 15. Brain Behav Immun. 2015. PMID: 25986216
An association analysis of HLA-DQB1 with narcolepsy without cataplexy and idiopathic hypersomnia with/without long sleep time in a Japanese population.
Miyagawa T, Toyoda H, Kanbayashi T, Imanishi A, Sagawa Y, Kotorii N, Kotorii T, Hashizume Y, Ogi K, Hiejima H, Kamei Y, Hida A, Miyamoto M, Ikegami A, Wada Y, Takami M, Fujimura Y, Tamura Y, Omata N, Masuya Y, Kondo H, Moriya S, Furuya H, Kato M, Kojima H, Kashiwase K, Saji H, Khor SS, Yamasaki M, Ishigooka J, Wada Y, Chiba S, Yamada N, Okawa M, Kuroda K, Kume K, Hirata K, Uchimura N, Shimizu T, Inoue Y, Honda Y, Mishima K, Honda M, Tokunaga K. Miyagawa T, et al. Among authors: ishigooka j. Hum Genome Var. 2015 Sep 17;2:15031. doi: 10.1038/hgv.2015.31. eCollection 2015. Hum Genome Var. 2015. PMID: 27081540 Free PMC article.
Current state of hypnotic use disorders: Results of a survey using the Japanese version of Benzodiazepine Dependence Self-Report Questionnaire.
Yamamoto M, Inada K, Enomoto M, Habukawa M, Hirose T, Inoue Y, Ishigooka J, Kamei Y, Kitajima T, Miyamoto M, Shinno H, Nishimura K, Ozone M, Takeshima M, Suzuki M, Yamashita H, Mishima K. Yamamoto M, et al. Among authors: ishigooka j. Neuropsychopharmacol Rep. 2021 Mar;41(1):14-25. doi: 10.1002/npr2.12149. Epub 2020 Dec 1. Neuropsychopharmacol Rep. 2021. PMID: 33259705 Free PMC article.
Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study.
Inoue Y, Shimizu T, Hirata K, Uchimura N, Ishigooka J, Oka Y, Ikeda J, Tomida T, Hattori N; Rotigotine Trial Group. Inoue Y, et al. Among authors: ishigooka j. Sleep Med. 2013 Nov;14(11):1085-91. doi: 10.1016/j.sleep.2013.07.007. Epub 2013 Aug 21. Sleep Med. 2013. PMID: 24055212 Clinical Trial.
Effect of Yokukansan for the Treatment of Idiopathic Rapid Eye Movement Sleep Behavior Disorder: A Retrospective Analysis of Consecutive Patients.
Matsui K, Sasai-Sakuma T, Ishigooka J, Nishimura K, Inoue Y. Matsui K, et al. Among authors: ishigooka j. J Clin Sleep Med. 2019 Aug 15;15(8):1173-1178. doi: 10.5664/jcsm.7816. J Clin Sleep Med. 2019. PMID: 31482840 Free PMC article.
CONCLUSIONS: Considering the effectiveness of YKS and the low likelihood of adverse events, YKS should be considered as a potential treatment for patients with RBD. CITATION: Matsui K, Sasai-Sakuma T, Ishigooka J, Nishimura K, Inoue Y. Effect of yokukansan for the t …
CONCLUSIONS: Considering the effectiveness of YKS and the low likelihood of adverse events, YKS should be considered as a potential treatmen …
150 results